Invion completes mid stage clinical trial for autoimmune disease drug

Australian drug development company Invion (ASX:  IVX) on Monday said it has completed its Phase II clinical trial for the drug to treat autoimmune disease, systemic lupus (SLE).

Chief medical officer, Mitchell Glass, said: “We are pleasedthat the data from this trial support the dose escalation that has underpinned the strategy for ala-Cpn10.”

The company said even though the data results are quite variable there is a consistency in responses. Invion said the drug candidate will need scale-up and longer term toxicology to extend these findings from one month to longer term studies in larger groups of subjects.